Adaptimmune Therapeutics

$5.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (+3.32%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, and ETFs commission-free!

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. The listed name for ADAP is Adaptimmune Therapeutics plc American Depositary Shares.

CEO

Adrian Rawcliffe

Employees

400

Headquarters

Abingdon, Oxfordshire

Founded

2014

Market Cap

925.78M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.15M

High Today

$5.71

Low Today

$5.30

Open Price

$5.43

Volume

577.71K

52 Week High

$13.40

52 Week Low

$2.00

Collections

Analyst Ratings

50%

of 8 ratings

Buy

50%

Hold

50%

Sell

ADAP Earnings

-$0.33

-$0.22

-$0.11

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market